Vera Therapeutics Newsroom

J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $75

Futu NewsNov 5 20:31 · Ratings

Vera Therapeutics Prices $300M Offering at $42 per Share

Seeking AlphaOct 30 14:21

Vera Therapeutics Price Target Raised to $64 From $56 at Guggenheim

Yahoo FinanceOct 29 21:25

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

GlobeNewswireOct 29 05:37

Express News | Vera Therapeutics Announces Proposed Public Offering of Class a Common Stock

BreakingsOct 29 05:37

Press Release: Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dow JonesOct 29 05:37

Express News | Vera Therapeutics Inc Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing

BreakingsOct 29 05:30

Vera Stock Closes 15% Higher in Wake of Positive Atacicept Data

Seeking AlphaOct 29 04:17

Sector Update: Health Care Stocks Rise Late Afternoon

MT NewswiresOct 29 03:59

Vera Therapeutics Analyst Ratings

BenzingaOct 29 00:36 · Ratings

Vera Therapeutics Shares Jump After Supportive Data From Phase 2b Trial of Kidney Disease Drug Candidate

MT NewswiresOct 28 23:55

Vera Therapeutics (VERA.US) rose 13% - positive results achieved in kidney disease research.

Vera Therapeutics (VERA.US) announced that the atacicept treatment trial results showed its potential to prevent kidney failure in patients with IgA nephropathy, leading to a sharp 13% increase in the company's stock price on Monday. The company stated that the phase 2b trial demonstrated stable kidney function in patients with chronic kidney disease after 96 weeks of long-term observation, which is caused by the accumulation of the protein IgA in the kidneys. The company plans to announce the primary results of the phase 3 trial in the second quarter of 2025 and later submit a biologics license application to the US Food and Drug Administration later this year.

AASTOCKSOct 28 22:47

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

BenzingaOct 28 22:33

Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $64

Futu NewsOct 28 22:31 · Ratings

Evercore Maintains Vera Therapeutics(VERA.US) With Buy Rating, Raises Target Price to $75

Futu NewsOct 28 22:31 · Ratings

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

BenzingaOct 28 22:14

A Quick Look at Today's Ratings for Vera Therapeutics(VERA.US), With a Forecast Between $60 to $75

Futu NewsOct 28 21:00 · Ratings

Express News | Vera Therapeutics Inc : Guggenheim Raises Target Price to $64 From $56

BreakingsOct 28 18:35

Promising Clinical Data and Strong Financials Justify Buy Rating for Vera Therapeutics Amid Atacicept's Potential in IgAN

TipRanksOct 28 03:05 · Ratings

Express News | Vera Therapeutics Inc - Trial Met Primary and Secondary Endpoints With Significant Proteinuria Reductions

BreakingsOct 27 07:30